Gene test could help doctors pick best Pre-Surgery breast cancer treatment

NCT ID NCT03749421

Ongoing Knowledge-focused Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether a gene test called Prosigna can help doctors choose the best treatment for women with a common type of breast cancer (HR+/HER2-) before surgery. About 60 women will have their treatment decisions recorded before and after the test results. The goal is to see if the test changes what treatment is recommended.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Prosigna PAM-50 gene test
What this could lead to: If successful, this could show that a gene test helps personalize breast cancer treatment before surgery, potentially improving outcomes.
What could go wrong: This is a small, early study (60 people) that only measures if doctors change their minds, not if patients actually do better. The test may not improve survival or reduce side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.